FindTrial
Sign In

Lonsurf

DRUG3 trials

Sponsors

Holy Stone Healthcare Co., Ltd, Patrick Joseph Loehrer Sr., UNICANCER

Conditions

Advanced or Metastatic Colorectal Cancer (mCRC)Advanced or Metastatic Solid TumorsDPD DeficiencyMetastatic Colorectal CancerMetastatic Gastroesophageal AdenocarcinomaPancreatic CancerPancreatic Ductal Adenocarcinoma

Phase 1

First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
CompletedNCT03616574
Holy Stone Healthcare Co., LtdAdvanced or Metastatic Colorectal Cancer (mCRC), Advanced or Metastatic Solid Tumors
Start: 2019-04-09End: 2022-03-01Updated: 2022-09-21
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
TerminatedNCT04046887
Patrick Joseph Loehrer Sr.Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Start: 2019-09-11End: 2023-10-04Updated: 2024-01-05

Phase 2

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
RecruitingNCT06245356
UNICANCERDPD Deficiency, Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma
Start: 2025-03-21End: 2028-10-21Target: 73Updated: 2025-12-10

Related Papers

Phase I study of trifluridine/tipiracil in combination with gemcitabine (gem) and nab-paclitaxel (nab-P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC).
Journal of Clinical Oncology2023-01-241 citations
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.
2022-11-043 citations